This document discusses the use of bisphosphonates to prevent bone loss in men receiving androgen deprivation therapy for prostate cancer and in women receiving adjuvant therapy for breast cancer. Androgen deprivation therapy increases fracture risk by decreasing bone mineral density and increasing bone turnover. The ZOMETA 705 study examined using bisphosphonates to prevent bone loss in men receiving androgen deprivation therapy. Several other studies discussed examined using bisphosphonates like risedronate, clodronate and zoledronic acid to prevent bone loss in women receiving chemotherapy or adjuvant hormonal therapy for breast cancer. The Z-FAST/ZO-FAST study specifically examined if zoledronic acid could protect against bone loss caused by the breast cancer drug an

1. Role of Bisphosphonates in Men
With Prostate Cancer Receiving
Androgen Deprivation Therapy

2. Bone Loss in Men

3. Androgen Deprivation Therapy
Increases Fracture Risk

4. Androgen Deprivation Therapy
Decreases Bone Mineral Density

5. Androgen Deprivation Therapy
Increases Bone Turnover

6. Why Are the Unintended Skeletal
Effects of Treatment Important?

7. ZOMETA 705: Bone Loss Prevention
Study

8. ZOMETA 705: Bone Loss Prevention
Study

11. Hormone- and Chemotherapy-Induced
Bone Loss in Women With Breast
Cancer

12. Adjuvant Therapy: Key Issues

13. Bone Loss in Cancer

14. Breast Cancer Associated With High
Vertebral Fracture Risk

15. Incidence of Chemotherapy-Induced
Ovarian Failure

16. Protection of the Normal Skeleton:
Clodronate and Chemotherapy

17. Risedronate to Prevent Bone Loss in
Women With Chemotherapy-Induced
Ovarian Failure

18. Risedronate to Prevent Bone Loss in
Women With Chemotherapy-Induced
Ovarian Failure

19. Interaction of Tamoxifen With
Risedronate: Effects on BMD

20. ATAC Trial Design

21. Probability of First Event in Receptor-
Positive Population

22. Significant Difference in Predefined
Adverse Events

23. Fractures in the ATAC Study

24. ATAC Lumbar Spine BMD: Percent
Change at Year 1

25. ATAC Total Hip BMD: Percent Change
at 1 Year

26. Bone Resorption (NTX): Percent
Change From Baseline

27. Bone Formation (iB-ALP): Percent
Change From Baseline

28. BMD in Premenopausal Breast Cancer
Patients Receiving Adjuvant Hormonal
Therapy (ABCSG-012)

29. BMD in Premenopausal Breast Cancer
Patients Receiving Adjuvant Hormonal
Therapy (ABCSG-012)

30. Zoledronic Acid Protects Against
Anastrozole-Induced Bone Loss

31. Z-FAST/ZO-FAST: Study Design

32. Z-FAST/ZO-FAST: Entry Criteria and
Stratification

33. Z-FAST/ZO-FAST: Study Endpoints

34. Conclusions